Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating, genetic, blistering condition caused by the absence of type VII collagen (C7) resulting in wounding. One major barrier to clinical trial development is the lack of understanding of the natural history of RDEB wounds, as the measurement of wound change has not been studied prospectively or validated. We conducted a longitudinal observational study of 13 participants with RDEB, that were not currently participating in interventional clinical trials.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have